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Objective: To investigate the genetic contribution in a large scale 
study of hand osteoarthritis (HOA) in Iceland using an extensive 
genealogy database of the Icelandic population. 
Patients and methods: As part of an ongoing study, patients 
with HOA have been actively registered through nationwide clini- 
cal and surgical registers, radiology clinics and ergotherapy cen- 
ters. At present 2917 HOA patients, comprising 1% of the 
Icelandic population, have been registered through the above 
channels. The patient phenotypes used are mild and severe inter- 
phalangeal (IP) OA and mild and severe thumb" base OA (CMC) 
based on clinical and radiological findings. Two methods were 
used to investigate the genetic contribution: (1) The average pair- 
wise kinship coefficient (KC) of the patients, and (2) the relative 
risk (RR) of BOA for relatives. In each case the results were com- 
pared with 1000 control sets of similar composition with regard to 
number, age and sex, generated from the genealogy database. 
Results: The KC for patients was significantly higher than for the 
control sets and increased with increased severity of both IP and 
CMC involvement. The RR of HOA for sisters of females in the 
study was 2.0 (p<0.001) while the RR for spouses was not signif- 
icantly different from controls. The RR increased with severity. 
Thus, sisters of patients with severe IP had a RR of 5.0 and 
severe CMC 6.9. 
Conclusions: Patients seeking medical services for HOA are 
more related to each other than matched controls, supporting the 
role of a genetic component in the disease. The degree of rela- 
tionship increases with increasing severity of HOA, both of IP and 
CMC involvement. The relative risks are consistent with an addi- 
tive model, i.e. negligible dominance. 
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Aim: To assess the effect of hyaluronan on joint space narrowing 
and additional symptom control in patients with osteoarthritis of 
the knee. 
Methods: The study was a 17-center, UK, randomized, placebo- 
controlled, double-blind study. Patients were assigned to receive 
three courses of three intra-articular injections of hyaluronan or 
saline during the 1-year study. The primary end point was the 
change in joint space width, measured by digital image analysis, 
over 1 year using weight-bearing, standardized radiographs. 
Uncontrolled use of analgesics and anti-inflammatory drugs was 
permitted. Secondary end points were pain changes monitored 
by pain scales, Lesquesne Index and the SF-36 with LOCF analy- 
sis. 
Results- In all, 408 patients were enrolled, 319 completed, and 
there was complete data for 273. The two groups were compara- 
ble at entry with a mean age of 64.2 years and 68% were female. 
Hyaluronan reduced the progression of joint space narrowing in 
those patients with a greater joint space at entry; hyaluronan 
mean joint space loss was 0.13mm (sd = 1.1), control group mean 
joint space loss was 0.55mm (sd = 1.0) [p= 0.021]. Both groups 
consumed anti-inflammatory drugs for 67% of the time, and 96% 
were on either analgesics or anti-inflammatory drugs. Despite 
this, the hyaluronan group showed significant improvement in 
pain over the control group at 11, 35, 52 weeks by VAS pain on 
walking [p=0.017, p=0.008, p=0.047] and categorical pain. At all 
time points the adjusted mean effect size favored the hyaluronan. 
The blinded assessor's global assessment gave significant 
improvements for the hyaluronan group over the placebo at 4, 28 
and 38 weeks. Tolerability was good. 
Conclusions. Repeat cycles of hyaluronan (mw 500-73OKDa) 
give a statistically significant delay in radiological joint space nar- 
rowing of the knee, within one year, in osteoarthritic patients with 
a larger joint space at baseline. During the study significant pain 
improvement was seen in the hyaluronan group despite most 
being on unlimited anti-inflammatory drugs and analgesics. The 
repeated cycles of three hyaluronan injections were safe. 
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Aim: The aim of this study was to analyze the effect of a single 
amino acid substitution in collagen II found in the patient with an 
early onset of osteoarthritis on interaction with collagen IX and on 
a skeletal development of the transgenic mice expressing the 
mutated gene. 
Methods: In this study, we examined molecular interactions 
between mutant collagen II with a Cys substitution for Arg-c~l - 
519 and collagen IX. In addition, we present an analysis of trans- 
genic mice that express human COL2A1 harboring the same 
mutation. 
Results: Binding of collagen IX to recombinant collagen II vari- 
ants that lack particular D-periods indicate that the C-terminal 
region of collagen II contains domains with a high affinity for col- 
lagen IX. It was also shown that a Cys substitution for Arg-c(1-519 
changes electrostatic properties of the mutation site, increases 
the affinity of mutant collagen II for collagen IX, and possibly influ- 
ences the specificity of the interaction. Study showed that rans- 
genic mice harboring two copies of the mutated human collagen 
II gene were smaller than their normal littermates and had a cleft 
palate. Electron microscopy of cartilage revealed a decrease in 
density of collagen fibrils. 
Conclusions: These results suggest that a Cys substitution for 
Arg-(~1-519 in collagen II does not only alter collagen tl fibdl for- 
mation, but also changes the molecular interactions with collagen 
IX and causes developmental berrations in transgenic mice that 
express the mutated gene. 
